Benzinga | Jun 14, 2021 08:09AM EDT

Aligos Therapeutics Announces Pipeline Update and Upcoming Presentations at the European Association for the Study of the Liver's Digital International Liver Congress 2021

-Five scientific posters to be presented at upcoming EASL ILC meeting

- All 4 Aligos CHB development candidates continue to advance -- STOPS(tm) molecule and CAM drug candidates are currently being evaluated in CHB subjects - ASO and siRNA drug candidates are on track to enter clinical development in H2 2021 and H1 2022, respectively

-Antiviral activity data from at least one cohort of CHB patients for ALG-010133 and ALG-000184 expected to be presented in H2 2021